The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Best-Worst Scaling Experiment.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
accepted:
19
09
2020
pubmed:
8
10
2020
medline:
1
9
2021
entrez:
7
10
2020
Statut:
ppublish
Résumé
Mental and behavioural disorders (MBDs) and interventions targeting MBDs lead to costs and cost savings in the healthcare sector, but also in other sectors. The latter are referred to as intersectoral costs and benefits (ICBs). Interventions targeting MBDs often lead to ICBs in the education and criminal justice sectors, yet these are rarely included in economic evaluations. This study aimed to investigate the attitudes held by health economists and health technology assessment experts towards education and criminal justice ICBs in economic evaluations and to quantify the relative importance of these ICBs in the context of MBDs. An online survey containing open-ended questions and two best-worst scaling object case studies was conducted in order to prioritise a list of 20 education ICBs and 20 criminal justice ICBs. Mean relative importance scores for each ICB were generated using hierarchical Bayes analysis. Thirty-nine experts completed the survey. The majority of the respondents (68%) reported that ICBs were relevant, but only a few (32%) included them in economic evaluations. The most important education ICBs were "special education school attendance", "absenteeism from school", and "reduced school attainment". The most important criminal justice ICBs were "decreased chance of committing a crime as a consequence/effect of mental health programmes/interventions", "jail and prison expenditures", and "long-term pain and suffering of victims/victimisation". This study identified the most important education and criminal justice ICBs for economic evaluations of interventions targeting MBDs and suggests that it could be relevant to include these ICBs in economic evaluations.
Identifiants
pubmed: 33026633
doi: 10.1007/s40273-020-00966-8
pii: 10.1007/s40273-020-00966-8
pmc: PMC7790798
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
99-108Références
Br J Psychiatry. 1998 Jun;172:477-84
pubmed: 9828986
Alcohol Alcohol. 2016 May;51(3):367-75
pubmed: 26493100
J Child Psychol Psychiatry. 2014 Jun;55(6):714-32
pubmed: 24580503
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
J Ment Health Policy Econ. 2013 Dec;16(4):179-86
pubmed: 24526586
Eur Child Adolesc Psychiatry. 2014 Jul;23(7):587-98
pubmed: 24166532
EMBO Rep. 2016 Sep;17(9):1245-9
pubmed: 27491723
J Ment Health Policy Econ. 1999 Sep 1;2(3):133-134
pubmed: 11967421
Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):77-84
pubmed: 26757960
Int J Clin Pharm. 2016 Jun;38(3):655-62
pubmed: 26846316
Pharmacoeconomics. 2017 Sep;35(9):895-908
pubmed: 28597368
Pharmacoeconomics. 2020 Oct;38(10):1135-1145
pubmed: 32696192
Appl Health Econ Health Policy. 2019 Oct;17(5):577-590
pubmed: 31098947
Pharmacoeconomics. 2008;26(4):269-80
pubmed: 18370563
Value Health. 2011 Jun;14(4):403-13
pubmed: 21669364
Eur J Health Econ. 2009 Oct;10(4):357-9
pubmed: 19618224
Aust N Z J Psychiatry. 2017 Dec;51(12):1198-1211
pubmed: 28565923
BMC Psychiatry. 2014 Aug 27;14:237
pubmed: 25159271
J Health Econ. 2007 Jan;26(1):171-89
pubmed: 16707175
Int J Technol Assess Health Care. 2017 Jan;33(2):251-260
pubmed: 28641592